CryoLife, Inc. Gross Margin

Gross Margin of CRY for past 10 years: annual, quarterly and twelve month trailing (TTM) including Gross Margin growth rates and interactive chart. Gross profit margin shows the percentage of revenue that exceeds a company's costs of goods sold. It illustrates how well a company is generating revenue from the costs involved in producing their products and services. The higher the margin, the more effective the company's management is in generating revenue for each dollar of cost. Gross profit margin is calculated by subtracting the cost of goods sold from total revenue for the period and dividing that number by revenue. If a company has $200 million in revenue and $80 million in cost of goods sold, the gross margin is 60%.

Highlights and Quick Summary

  • Gross Margin for the quarter ending March 30, 2021 was 61.09% (a 3.04% increase compared to previous quarter)
  • Year-over-year quarterly Gross Margin increased by 0.36%
  • Annual Gross Margin for 2020 was 60.82% (a -2.42% decrease from previous year)
  • Annual Gross Margin for 2019 was 62.33% (a 1.0% increase from previous year)
  • Annual Gross Margin for 2018 was 61.71% (a -5.25% decrease from previous year)
  • Twelve month Gross Margin ending March 30, 2021 was 60.48% (a -0.25% decrease compared to previous quarter)
  • Twelve month trailing Gross Margin decreased by -5.78% year-over-year
Trailing Gross Margin for the last four month:
30 Mar '21 30 Dec '20 29 Sep '20 29 Jun '20
60.48% 60.63% 62.67% 64.19%
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Gross Margin of CryoLife, Inc.

Most recent Gross Marginof CRY including historical data for past 10 years.

Interactive Chart of Gross Margin of CryoLife, Inc.

CryoLife, Inc. Gross Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 61.09%
2020 59.29% 60.76% 60.87% 61.68% 60.82%
2019 66.79% 66.62% 66.02% 65.58% 62.33%
2018 65.81% 66.94% 66.94% 63.32% 61.71%
2017 68.84% 67.87% 68.81% 65.5% 65.13%
2016 69.28% 65.81% 64.36% 64.21% 63.46%
2015 66.56% 62.62% 60.67% 58.13% 62.18%
2014 60.93% 64.2% 64.53% 62.89% 63.12%
2013 62.84% 64.41% 64.08% 65.5% 64.21%
2012 64.16% 63.75% 64.39% 65.92% 64.55%
2011 63.74% 63.78% 64.85% 61.28% 63.4%
2010 60.18% 53.52% 60.72% 58.61%

Business Profile of CryoLife, Inc.

Sector: Healthcare
Industry: Medical Devices
CryoLife, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; and cardiac laser therapy products, such as SolarGen 2100s Console and SoloGrip III disposable handpieces. Further, the company sells CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as offers pyrolytic carbon coating services to other medical device manufacturers. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.